CO6920289A2 - Composición farmacéutica oftalmológica tópica que contiene regorafenib. - Google Patents
Composición farmacéutica oftalmológica tópica que contiene regorafenib.Info
- Publication number
- CO6920289A2 CO6920289A2 CO13300167A CO13300167A CO6920289A2 CO 6920289 A2 CO6920289 A2 CO 6920289A2 CO 13300167 A CO13300167 A CO 13300167A CO 13300167 A CO13300167 A CO 13300167A CO 6920289 A2 CO6920289 A2 CO 6920289A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical composition
- composition containing
- topical ophthalmic
- ophthalmic pharmaceutical
- containing regorafenib
- Prior art date
Links
- 239000002138 L01XE21 - Regorafenib Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 title 1
- 229960004836 regorafenib Drugs 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11171719 | 2011-06-28 | ||
| EP12155281 | 2012-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6920289A2 true CO6920289A2 (es) | 2014-04-10 |
Family
ID=46456546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13300167A CO6920289A2 (es) | 2011-06-28 | 2013-12-26 | Composición farmacéutica oftalmológica tópica que contiene regorafenib. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20140296301A1 (es) |
| EP (1) | EP2726059A1 (es) |
| JP (1) | JP5998213B2 (es) |
| KR (1) | KR20140048218A (es) |
| CN (1) | CN103889399A (es) |
| AP (1) | AP2013007335A0 (es) |
| AR (1) | AR086800A1 (es) |
| AU (1) | AU2012277905A1 (es) |
| BR (1) | BR112013033831A2 (es) |
| CA (1) | CA2840329A1 (es) |
| CL (1) | CL2013003700A1 (es) |
| CO (1) | CO6920289A2 (es) |
| CR (1) | CR20130693A (es) |
| CU (1) | CU24163B1 (es) |
| DO (1) | DOP2013000314A (es) |
| EA (1) | EA201400064A1 (es) |
| EC (1) | ECSP13013106A (es) |
| GT (1) | GT201300322A (es) |
| HK (1) | HK1197176A1 (es) |
| MX (1) | MX2013015287A (es) |
| PE (1) | PE20141031A1 (es) |
| TN (1) | TN2013000533A1 (es) |
| UY (1) | UY34166A (es) |
| WO (1) | WO2013000917A1 (es) |
| ZA (1) | ZA201400646B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005289100B2 (en) | 2004-09-29 | 2011-11-03 | Bayer Healthcare Llc | Thermodynamically stable form of bay 43-9006 tosylate |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| UY35183A (es) * | 2012-12-21 | 2014-07-31 | Bayer Healthcare Llc | Composición farmacéutica oftalmológica tópica que contiene regorafenib |
| WO2015011659A1 (en) * | 2013-07-24 | 2015-01-29 | Dr. Reddys Laboratories Limited | Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib |
| CN103923000A (zh) * | 2014-01-29 | 2014-07-16 | 苏州晶云药物科技有限公司 | 几种新晶型及其制备方法 |
| CN104546776B (zh) * | 2015-02-10 | 2017-08-22 | 杭州朱养心药业有限公司 | 瑞戈非尼片剂药物组合物和制法 |
| EP4335418A3 (en) * | 2015-06-06 | 2024-05-22 | Cloudbreak Therapeutics, LLC | Compositions and methods for treating pterygium |
| AU2017274195B2 (en) | 2016-06-02 | 2022-04-07 | Ads Therapeutics Llc | Compositions and methods of using nintedanib for improving glaucoma surgery success |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2732222B1 (fr) * | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux |
| EP2020243B1 (en) * | 2002-05-28 | 2018-08-15 | AstraZeneca AB | Topically applicable pharmaceutical preparation |
| EP1663978B1 (en) * | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| EP1885336B1 (en) | 2005-05-10 | 2009-04-15 | Alcon, Inc. | Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders |
| CA2611720A1 (en) | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
| WO2007064752A2 (en) | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
| JP2009519267A (ja) * | 2005-12-15 | 2009-05-14 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア |
| EP1962803A1 (en) | 2005-12-23 | 2008-09-03 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| WO2008027341A2 (en) | 2006-08-30 | 2008-03-06 | Merck & Co., Inc. | Topical ophthalmic formulations |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| CN101678006A (zh) * | 2007-05-11 | 2010-03-24 | 参天制药株式会社 | 含有非麦角类的选择性d2受体激动剂作为有效成分的后眼部疾病的预防或治疗剂 |
| DE102007055341A1 (de) * | 2007-11-19 | 2009-05-20 | Bayer Animal Health Gmbh | Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren |
| EP3165606A1 (en) | 2009-05-01 | 2017-05-10 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| EA201190337A1 (ru) | 2009-07-16 | 2012-06-29 | Глаксо Вэллкам Мэньюфэкчуринг Пти Лтд. | Способ лечения |
-
2012
- 2012-06-26 CA CA2840329A patent/CA2840329A1/en not_active Abandoned
- 2012-06-26 MX MX2013015287A patent/MX2013015287A/es not_active Application Discontinuation
- 2012-06-26 EP EP12731396.3A patent/EP2726059A1/en not_active Withdrawn
- 2012-06-26 AU AU2012277905A patent/AU2012277905A1/en not_active Abandoned
- 2012-06-26 WO PCT/EP2012/062365 patent/WO2013000917A1/en active Application Filing
- 2012-06-26 EA EA201400064A patent/EA201400064A1/ru unknown
- 2012-06-26 JP JP2014517661A patent/JP5998213B2/ja not_active Expired - Fee Related
- 2012-06-26 BR BR112013033831A patent/BR112013033831A2/pt not_active IP Right Cessation
- 2012-06-26 PE PE2013002872A patent/PE20141031A1/es not_active Application Discontinuation
- 2012-06-26 CN CN201280042504.9A patent/CN103889399A/zh active Pending
- 2012-06-26 AP AP2013007335A patent/AP2013007335A0/xx unknown
- 2012-06-26 KR KR1020147002095A patent/KR20140048218A/ko not_active Application Discontinuation
- 2012-06-26 US US14/128,356 patent/US20140296301A1/en not_active Abandoned
- 2012-06-26 CU CU20130168A patent/CU24163B1/es active IP Right Grant
- 2012-06-27 UY UY0001034166A patent/UY34166A/es not_active Application Discontinuation
- 2012-06-28 AR ARP120102339A patent/AR086800A1/es active Pending
-
2013
- 2013-12-20 CR CR20130693A patent/CR20130693A/es unknown
- 2013-12-23 GT GT201300322A patent/GT201300322A/es unknown
- 2013-12-23 CL CL2013003700A patent/CL2013003700A1/es unknown
- 2013-12-24 EC EC2013013106A patent/ECSP13013106A/es unknown
- 2013-12-26 DO DO2013000314A patent/DOP2013000314A/es unknown
- 2013-12-26 CO CO13300167A patent/CO6920289A2/es not_active Application Discontinuation
- 2013-12-27 TN TNP2013000533A patent/TN2013000533A1/fr unknown
-
2014
- 2014-01-27 ZA ZA2014/00646A patent/ZA201400646B/en unknown
- 2014-10-22 HK HK14110517A patent/HK1197176A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2840329A1 (en) | 2013-01-03 |
| NZ619229A (en) | 2016-04-29 |
| EA201400064A1 (ru) | 2014-05-30 |
| MX2013015287A (es) | 2014-03-31 |
| ZA201400646B (en) | 2015-11-25 |
| CU24163B1 (es) | 2016-03-31 |
| ECSP13013106A (es) | 2014-01-31 |
| KR20140048218A (ko) | 2014-04-23 |
| CN103889399A (zh) | 2014-06-25 |
| JP5998213B2 (ja) | 2016-09-28 |
| US20140296301A1 (en) | 2014-10-02 |
| BR112013033831A2 (pt) | 2017-02-14 |
| AP2013007335A0 (en) | 2013-12-31 |
| EP2726059A1 (en) | 2014-05-07 |
| AU2012277905A8 (en) | 2014-01-30 |
| PE20141031A1 (es) | 2014-08-21 |
| DOP2013000314A (es) | 2014-04-15 |
| CU20130168A7 (es) | 2014-04-24 |
| AR086800A1 (es) | 2014-01-22 |
| JP2014518233A (ja) | 2014-07-28 |
| AU2012277905A1 (en) | 2014-01-16 |
| CL2013003700A1 (es) | 2014-07-18 |
| GT201300322A (es) | 2014-11-13 |
| UY34166A (es) | 2013-01-31 |
| HK1197176A1 (en) | 2015-01-09 |
| WO2013000917A1 (en) | 2013-01-03 |
| CR20130693A (es) | 2016-05-02 |
| TN2013000533A1 (en) | 2015-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| SMT201700008B (it) | Composizione farmaceutica | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| BR112015004936A2 (pt) | composição farmacêutica revestida contendo regorafenib | |
| DK3181128T3 (da) | Farmaceutisk nilotinib-sammensætning | |
| DK3192501T3 (da) | Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner | |
| BR112014003052A2 (pt) | composições farmacêuticas | |
| DK3246018T3 (da) | Farmaceutisk sammensætning | |
| CO6920289A2 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib. | |
| ES2985024T3 (es) | Nueva composición farmacéutica | |
| CO6930367A2 (es) | Composiciones farmaceúticas | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| EE201300005A (et) | Ravimkoostis | |
| BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
| BR112014009950A2 (pt) | composto dissubstituído, compostos e composição farmacêutica | |
| BR112013022556A2 (pt) | composição farmacêutica aquosa semissólida contendo tapentadol | |
| CO7061076A2 (es) | Composición farmacéutica que contiene un derivado de dihidroquinazolina antiviralmente activo | |
| HK1204563A1 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| HK1204992A1 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| DK2815752T3 (da) | Oral farmaceutisk sammensætning | |
| SMT201600097B (it) | Composizione farmaceutica liquida che comprende nitisone | |
| CO7010828A2 (es) | Preparación farmacéutica que comprende ßciclodextrina sustituida | |
| BR112014009761A2 (pt) | composição oftálmica | |
| BR112013031544A2 (pt) | composição tópica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |